Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)

被引：0
|
作者：
Park, Haeseong
Geyer, Susan Michelle
Klute, Kelsey
Bleeker, Jonathan
King, Daniel
Strickland, Matthew
Goodrich, Austin
Carlisle, Destin
Shergill, Ardaman
O'Reilly, Eileen Mary
Meyerhardt, Jeffrey A.
Shah, Manish A.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Sanford Hlth, Sioux Falls, SD USA
[6] Northwell Hlth, New Hyde Pk, NY USA
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4175
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting
    Billard, Karine
    Mortier, Laurent
    Dereure, Olivier
    Dalac, Sophie
    Montaudie, Henri
    Legoupil, Delphine
    Dutriaux, Caroline
    De Quatrebarbes, Julie
    Maubec, Eve
    Leccia, Marie-Therese
    Granel-Brocard, Florence
    Brunet-Possenti, Florence
    Arnault, Jean-Philippe
    Gaudy-Marqueste, Caroline
    Pages, Cecile
    Saiag, Philippe
    L'Orphelin, Jean-Matthieu
    Zehou, Ouidad
    Lesimple, Thierry
    Allayous, Clara
    Porcher, Raphael
    Oriano, Bastien
    Dalle, Stephane
    Lebbe, Celeste
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
  • [2] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
    Shen, Lin
    Zhang, Yanqiao
    Li, Ziyu
    Zhang, Xiaotian
    Gao, Xiangyu
    Liu, Bo
    Wang, Yusheng
    Ba, Yi
    Li, Ning
    Zhang, Ruixing
    Zhang, Jingdong
    Chen, Ye
    Chen, Jian
    Huang, Mingzhu
    Fu, Yang
    Liu, Mulin
    Liu, Zheng
    Zhao, Jun
    Li, Wei
    Wei, Jia
    Li, Changzheng
    Xu, Nong
    Guo, Zengqing
    Cao, Bangwei
    Liu, Lian
    Nie, Peng
    Wan, Lixin
    Sheng, Lili
    Liu, Zhenyang
    He, Yifu
    Gu, Kangsheng
    Wu, Guowu
    Wang, Weibo
    Zhang, Futong
    Qiu, Wensheng
    Guo, Jun
    Ying, Jieer
    Pan, Hongming
    Xu, Huiting
    Yuan, Yuan
    Bai, Yuansong
    Wang, Zhenghua
    Xu, Jiye
    Zhao, Xuehong
    Liu, Hao
    Zhang, Xizhi
    Dai, Wenxiang
    Xu, Hongyan
    Liu, Ming
    Xie, Lin
    NATURE MEDICINE, 2025, : 1163 - 1170
  • [3] ECHO-310: A phase 3, randomized trial of epacadostat plus nivolumab plus chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.
    Cohen, Ezra E. W.
    Mehra, Ranee
    Psyrri, Amanda
    Bauman, Julie E.
    Schaub, Richard
    Zhou, Li
    Li, Li
    Jayaprakash, Vijayvel
    Guigay, Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Multicenter randomized phase II study of short course FOLFOX plus nivolumab (Nivo) followed by maintenance Nivo plus /- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA)
    Shah, Manish A.
    Mukherjee, Sarbajit
    Klute, Kelsey
    D'Angelo, Debra
    Khan, Sahrish
    Sanfilippo, Nicholas J.
    Christos, Paul J.
    Frakes, Jessica M.
    Delaney, Jessica
    Chatley, Sarah
    Lim, Kian-Huat
    Park, Haeseong
    Metha, Rutika
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.
    Mehta, Rutika
    Mukherjee, Sarbajit
    Klute, Kelsey
    Park, Haeseong
    Khan, Uqba
    Khan, Sahrish
    Puello, Carina
    Machado, Sabrina
    Christos, Paul J.
    Sanfilippo, Nicholas J.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Reddy, Sangeetha
    Emens, Leisha A.
    Overmoyer, Beth
    Lange, Paulina
    Dilullo, Molly K.
    Attaya, Victoria
    Kimmel, Jeffrey
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [7] FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.
    Lorenzen, Sylvie
    Thuss-Patience, Peter C.
    Knorrenschild, Jorge Riera
    Goekkurt, Eray
    Dechow, Tobias Nicolaas
    Hofheinz, Ralf-Dieter
    Luley, Kim Barbara
    Ettrich, Thomas Jens
    Pink, Daniel
    Lindig, Udo
    Folprecht, Gunnar
    Schuch, Gunter
    Bitzer, Michael
    Bolling, Claus
    Homann, Nils
    Junge, Sabine
    Pauligk, Claudia
    Gaiser, Timo
    Goetze, Thorsten Oliver
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Trifluridine/tipiracil plus oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
    Botsen, Damien
    Chabaud, Sylvie
    Perrier, Herve
    Ammarguellat, Hanifa
    Jestin-Le-Tallec, Veronique
    Olesinski, Jonathan
    Toullec, Clemence
    Aparicio, Thomas
    Ben Abdelghani, Meher
    Borg, Christophe
    Bouche, Olivier
    Coutzac, Clelia
    Devaud, Herve
    Di Fiore, Frederic
    Dubreuil, Olivier
    Evesque, Ludovic
    Huguenin, Bruno
    Muller, Marie
    Poureau, Pierre-Guillaume
    Oularue, Emilie
    Tougeron, David
    Zaanan, Aziz
    Ammari, Samy
    Carvalho, Nicolas De Sousa
    Decazes, Pierre
    De La Fouchardiere, Christelle
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1281 - 1287
  • [9] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [10] Zanidatamab plus chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
    Elimova, Elena
    Ajani, Jaffer A.
    Burris, Howard A., III
    Denlinger, Crystal S.
    Iqbal, Syma
    Kang, Yoon-Koo
    Kim, Yeul Hong Hong
    Lee, Keun-Wook
    Lin, Bruce
    Mehta, Rutika
    Oh, Do-Youn
    Rha, Sun Young
    Soel, Yong Mi
    Boyken, Lisa
    Grim, Jonathan E.
    Ku, Geoffrey Yuyat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 347 - 347
12345